Search by company, ticker, drug, or red flag. Filter by investigation rating. Every record links to a structured report with a full source appendix.
| Company | Ticker | Drug | Phase | Status | Key Red Flag | Rating |
|---|---|---|---|---|---|---|
| ApexNova Therapeutics | APXV | ANX-204 · oral metabolic | Phase 2 | Complete | Primary endpoint missed (p = 0.062); claims built on exploratory subgroup | High Risk |
| Curiative Pharma | CURX | CUR-319 · NASH | Phase 3 | Complete | Registry primary endpoints differ from endpoints in the published topline | Critical Red Flags |
| Helixor Bio | HLXB | HLX-117 · ocular gene therapy | Phase 1/2 | Complete | n = 12; unblinded readout presented as efficacy evidence | Elevated Risk |
| Meridian Cell Sciences | MRDC | MRC-88 · solid-tumor CAR-T | Phase 2 | Monitoring | Commercial model assumes manufacturing yields not yet demonstrated | Watch |
| Novaris Gene | NVGN | NVG-7 · CRISPR rare disease | IND | Complete | No material discrepancy identified between disclosures and registry record | Low Concern |
| BlueSpruce Immunotherapeutics | BSPR | BSI-210 · checkpoint bispecific | Phase 1 | Monitoring | Early data with limited follow-up; durability claims premature | Watch |
| Vellicor Therapeutics | VLLC | VLC-102 · ALS | Phase 2/3 | Monitoring | Two timeline revisions; differential dropout between arms | Elevated Risk |
| Telomerx Bio | TELX | TLX-450 · senolytic | Preclinical | Complete | Human-capital claims rest on animal data presented with clinical-language framing | High Risk |
| Quantivir Sciences | QTVS | QTV-601 · antiviral | Phase 2 | Complete | Disclosure inconsistencies across quarters; possible fraud indicators — documented, under review | Critical Red Flags |
Report cards show ticker, company, drug, phase, investigation rating, and publication date.
Key finding: the primary endpoint in the published topline differs from the primary endpoint registered two years earlier. The switch is not disclosed in investor materials.
Key finding: “breakthrough Phase 2 efficacy” rests on a post-hoc subgroup; the primary endpoint missed significance in a 34-patient trial.
Key finding: unblinded, single-arm data from twelve patients presented with the framing of controlled efficacy evidence.
The database is a demonstration. Commission a dedicated investigation and it starts with a scoped evidence plan.
